Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997041 | 0.85 | CDK1 (0.48) | MEN1KMT2ALMNACYP1A2PDE4A | |
| SCHEMBL13601281 | 0.85 | ALDH1A1 (0.47) | MEN1KMT2AMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL3852234 | 0.85 | KDM4C (0.49) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL3304345 | 0.84 | KCNH3 (0.39) | MAPTSMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL3302949 | 0.82 | PDE10A (0.42) | MAPTCYP3A4VNN1HDAC1HDAC6 | |
| SCHEMBL3302007 | 0.81 | CDK1 (0.54) | MEN1KMT2AMAPTPABPC1SMN1; SMN2 | |
| SCHEMBL3298944 | 0.81 | AURKA (0.56) | KDM4CCLK4 | |
| SCHEMBL17017484 | 0.81 | KDM4C (0.59) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL30850661 | 0.81 | KDM4C (0.59) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL17443005 | 0.80 | MAP2K4 (0.43) | MEN1KMT2AMAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
| US-20180258090-A1 | IMAGING AGENTS FOR NEURAL FLUX | UNITED STATES DEPARTMENT OF ENERGY | 2018-09-13 | — | — | US | disclosed |
| WO-2016011394-A1 | IMAGING AGENTS FOR NEURAL FLUX | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011394-A1 | IMAGING AGENTS FOR NEURAL FLUX | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-8592581-B2 | Trisubstituted purine derivatives | CYCLACEL LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2139893-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | CYCLACEL LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-7582642-B2 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-7582642-B2 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-7582642-B2 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| WO-2008122767-A2 | 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| EP-1529047-B1 | NEW PURINE DERIVATIVES | CYCLACEL LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| EP-1529047-A2 | NEW PURINE DERIVATIVES | Cyclacel Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016612-A2 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325983-A1 | NEW PURINE DERIVATIVES | C5, CYC1, CCNH | MEN1 882/4885KMT2A 3751/4885MAPT 3329/4885 |
| US-10519160-B2 | Imaging agents for neural flux | SLC18A2, SLC18A3, PMP22 | MEN1 417/4885KMT2A 4686/4885MAPT 186/4885 |
| US-20180258090-A1 | IMAGING AGENTS FOR NEURAL FLUX | SLC18A2, SLC18A3, PMP22 | MEN1 417/4885KMT2A 4686/4885MAPT 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.